Facebook
Twitter
LinkedIn
Forward
Farrell Wiggins MS, OTR/L, and Alexis Petteway, MS, OTR/L, provide insight into Occupational Therapy’s unique role in cancer rehabilitation. They explore the benefits of receiving OT in both the inpatient and outpatient settings. Importantly, they also discuss the how occupational therapists measure and address cancer and chemotherapy related symptoms and occupational challenges in cancer survivors.
|
Patti Morfeld, RN, BSN, OCNm discusses how to provide patient centered care for LGBTQ patients and families from registration through diagnosis, treatment and survivorship.
|
Cancer survivors may face many unique psychosocial challenges. Melissa Holt, DNP, PMHNP-BC and Lisa Kanser, PsyD discuss Acceptance and Commitment Therapy (ACT) is an evidence-based psychotherapeutic approach that can effectively teach patients skills to manage these challenges after completing cancer treatment. We will take you through case vignettes to show you how ACT can be applied to this patient population.
|
Tailored for medical providers, this session led by a physical therapist addresses challenges like speech and swallowing difficulties or pelvic floor issues in gynecological cancer. Explore the pivotal role of physical therapy in survivorship care plans and delve into current research supporting interventions for head and neck, gynecological, breast cancer, and other oncological conditions. Emphasizing interdisciplinary collaboration, we'll discuss the synergy between medical providers and physical therapists in delivering optimal cancer care. Additionally, learn the art of patient education in oncology rehabilitation, empowering medical providers to effectively communicate the role of physical therapy in cancer care.
|
Patients undergoing treatment for cancer utilize many medications that have relevant drug-gene interactions. The use of pharmacogenomic testing can assist with drug selection, drug dosing, and the development of personalized medication monitoring plans. Amber Cipriani, PharmD, BCOP, will describe some common examples of drug-gene interactions relevant to oncology. She will also discuss current efforts to expand the use of pharmacogenomic testing into current clinical practice.
|
Immunotherapy has made tremendous progress as cancer-directed therapy has evolved, particularly in the field of T cell-engaging therapies. Common and serious side effects of these types of therapies include Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS). Join us as Bejal Kikani, MSN, FNP-BC, WHNP-BC, discusses the recognition, grading, and treatment of these toxicities.
|
Jeremiah 'Jig' Deneve, DO, FACS, provides an overview of the natural history, treatment, and outcome for peritoneal carcinomatosis.
|
Megan McElfresh, PA-C, will review chimeric antigen receptor therapy, associated side effects, and the treatment or prevention of side effects.
|
This multidisciplinary Panel Presentation will describe the importance of CT-based lung cancer screening, indications and criteria for screening, the optimal structure and requirements of a screening program, and the current state of screening at UNC. We will present practical information relevant to providers who may order screening CT and/or may discuss screening with patients.
|
Allison Phillips, MPAP, MHPE, PA-C, reviews the clinical manifestations, underlying causes, and management of some of the most common emergencies facing patients undergoing cancer treatment, including Superior Vena Cava Syndrome, Hypercalcemia, and SIADH.
|